ArticleFrontiers in bioengineering and biotechnology2020
Multi-Path Optimization for Efficient Production of 2'-Fucosyllactose in an Engineered
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 54 citations in OpenAlex.
- A comprehensive safety evaluation of approved 2'-fucosyllactose for human nutritional applications in China.Frontiers in toxicology · 2026Article
- Synthesis of 2'-fucosyllactose using multi-enzyme cascade with cofactor regeneration.Scientific reports · 2025Article
- Development and application of synthetic biology tools for improved production of human breast milk components.Synthetic and systems biotechnology · 2025Review
- Biosynthesis and metabolic engineering of natural sweeteners.AMB Express · 2025Review
- Intensification of 2'-Fucosyllactose biosynthesis pathway by using a novel fucosyltransferase fromFrontiers in bioengineering and biotechnology · 2025Article
- Efficient production of 2'-fucosyllactose from fructose through metabolically engineered recombinant Escherichia coli.Microbial cell factories · 2024Article
- Multi-level metabolic engineering of Escherichia coli for high-titer biosynthesis of 2'-fucosyllactose and 3-fucosyllactose.Microbial biotechnology · 2022Article
- Synthesis as an Expanding Resource in Human Milk Science.Journal of the American Chemical Society · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
2'-fucosyllactose (2'-FL), one of the simplest but most abundant oligosaccharides in human milk, has been demonstrated to have many positive benefits for the healthy development of newborns. However, the high-cost production and limited availability restrict its widespread use in infant nutrition and further research on its potential functions. In this study, on the basis of previous achievements, we developed a powerful cell factory by using a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.